BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 9236749)

  • 1. Rising prescription drug costs: whose responsibility?
    Hill SR; Henry DD; Smith AJ
    Med J Aust; 1997 Jul; 167(1):6-7. PubMed ID: 9236749
    [No Abstract]   [Full Text] [Related]  

  • 2. Twenty-Year Nationwide Trends in Statin Utilization and Expenditure in Denmark.
    Mortensen MB; Falk E; Schmidt M
    Circ Cardiovasc Qual Outcomes; 2017 Jul; 10(7):. PubMed ID: 28698192
    [No Abstract]   [Full Text] [Related]  

  • 3. Use of cholesterol-lowering medications in the United States from 1991 to 1997.
    Siegel D; Lopez J; Meier J
    Am J Med; 2000 Apr; 108(6):496-9. PubMed ID: 10781783
    [No Abstract]   [Full Text] [Related]  

  • 4. Prescribing costs and patterns: authors' response.
    Walker J; Mathers N
    Br J Gen Pract; 2002 Jul; 52(480):587. PubMed ID: 12120741
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluating prescribing interventions.
    Wong G
    Br J Gen Pract; 2002 May; 52(478):412-3. PubMed ID: 12014546
    [No Abstract]   [Full Text] [Related]  

  • 6. Margaret McCartney: Second use patents--why do we have to prescribe branded Lyrica for pain?
    McCartney M
    BMJ; 2015 May; 350():h2734. PubMed ID: 25995105
    [No Abstract]   [Full Text] [Related]  

  • 7. Prescribing.
    Palmer K
    Practitioner; 1990 Oct; 234(1495):888-90. PubMed ID: 2131447
    [No Abstract]   [Full Text] [Related]  

  • 8. Prescribing and drug costs in the province of Ontario.
    Lexchin J
    Int J Health Serv; 1992; 22(3):471-87. PubMed ID: 1644510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs of therapeutic alternatives: physicians' knowledge.
    Griswold MW; Briceland LL; Lesar TS
    Ann Pharmacother; 1996; 30(7-8):882-3. PubMed ID: 8826578
    [No Abstract]   [Full Text] [Related]  

  • 10. High Costs and Caution Yield Slow Start for New Heart Drugs.
    Kuehn BM
    Circulation; 2018 Jan; 137(2):197-199. PubMed ID: 29311350
    [No Abstract]   [Full Text] [Related]  

  • 11. Changes to the Australian Pharmaceutical Benefit Scheme restrictions for biological disease-modifying antirheumatic drugs have influenced the use of leflunomide.
    Hopkins AM; Vitry AI; O'Doherty CE; Proudman SM; Wiese MD
    Int J Rheum Dis; 2017 Nov; 20(11):1795-1797. PubMed ID: 26176865
    [No Abstract]   [Full Text] [Related]  

  • 12. Trend of cost and utilization of COPD medication in Korea.
    Lee J; Lee JH; Kim JA; Rhee CK
    Int J Chron Obstruct Pulmon Dis; 2017; 12():27-33. PubMed ID: 28031708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in Opioid Prescription in Children and Adolescents in a Commercially Insured Population in the United States, 2004-2017.
    Gagne JJ; He M; Bateman BT
    JAMA Pediatr; 2019 Jan; 173(1):98-99. PubMed ID: 30419137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five-year evolution of drug prescribing in a university adult intensive care unit.
    Carron C; Voirol P; Eggimann P; Pannatier A; Chioléro R; Wasserfallen JB
    Appl Health Econ Health Policy; 2012 Sep; 10(5):355-8. PubMed ID: 22809277
    [No Abstract]   [Full Text] [Related]  

  • 15. Economics in epilepsy treatment choices: our certain fate?
    Heaney DC; Beran RG; Halpern MT
    Epilepsia; 2002; 43 Suppl 4():32-8. PubMed ID: 12059999
    [No Abstract]   [Full Text] [Related]  

  • 16. Experts' agency problems: evidence from the prescription drug market in Japan.
    Iizuka T
    Rand J Econ; 2007; 38(3):844-62. PubMed ID: 18478669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prescription patterns and costs of antidiabetic medications in a large group of patients.
    Gaviria-Mendoza A; Sánchez-Duque JA; Medina-Morales DA; Machado-Alba JE
    Prim Care Diabetes; 2018 Apr; 12(2):184-191. PubMed ID: 29196125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Pharmaceutical Benefits Scheme: time for radical surgery?
    Shaw J
    Med J Aust; 1988 Aug; 149(4):174-5. PubMed ID: 3173174
    [No Abstract]   [Full Text] [Related]  

  • 19. Physician and Patient Adjustment to Reference Pricing for Drugs.
    Robinson JC; Whaley C; Brown TT; Dhruva SS
    JAMA Netw Open; 2020 Feb; 3(2):e1920544. PubMed ID: 32022881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilar Filgrastim Use in the United States vs the European Union and Japan-Why Does It Lag Behind and What Can Be Done?
    Qureshi ZP; Nagai S; Bennett CL
    JAMA Oncol; 2019 Mar; 5(3):297-298. PubMed ID: 30508013
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.